Oppenheimer Reiterates Outperform and PT of $9 on Sequenom

by Emily Austin, Benzinga Staff Writer
July 8, 2011 8:59 AM | 12 seconds read |
Oppenheimer reiterated its Outperform rating on Sequenom SQNM. At the same time, the rating agency left its price target on the company's stock unchanged at $9. On Thursday, Sequenom closed the day at $7.90.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: ReiterationAnalyst RatingsHealth CareLife Sciences Tools & ServicesOppenheimer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!